marketcaparena
Search

    BLLN

    BillionToOne, Inc.

    Company overview

    Market capitalization
    $5.74B
    Employees
    713
    Latest publication
    2026-09-29
    About BillionToOne, Inc.

    BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USD
    Total Revenue109,448,000USD108,388,000USD96,053,000USD
    Cost Of Revenue32,341,000USD29,292,000USD27,449,000USD
    Gross Profit77,107,000USD79,096,000USD68,604,000USD
    Research Development17,315,000USD14,692,000USD14,250,000USD
    Selling General Administrative54,289,000USD46,570,000USD44,022,000USD
    Total Operating Expenses71,604,000USD61,262,000USD58,272,000USD
    Operating Income5,503,000USD17,834,000USD10,332,000USD
    Total Other Income Expense Net2,015,000USD675,000USD-4,035,000USD
    Interest Income4,694,000USD4,645,000USD3,258,000USD
    Interest Expense8,000USD10,000USD3,000USD
    Income Before Tax7,518,000USD18,509,000USD6,297,000USD
    Income Tax Expense-536,000USD539,000USD320,000USD
    Net Income8,054,000USD17,970,000USD5,977,000USD
    Net Income Applicable To Common Shares8,054,000USD——
    Net Interest Income—4,635,000USD3,255,000USD
    Tax Provision—539,000USD320,000USD
    Net Income From Continuing Ops—17,970,000USD5,977,000USD
    Ebit—18,519,000USD6,300,000USD
    Ebitda—21,509,000USD9,260,000USD
    Depreciation And Amortization—2,990,000USD2,960,000USD
    Reconciled Depreciation—2,990,000USD2,960,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USD
    Total Revenue305,112,000USD
    Cost Of Revenue96,654,000USD
    Gross Profit208,458,000USD
    Research Development49,384,000USD
    Selling General Administrative143,051,000USD
    Total Operating Expenses192,435,000USD
    Operating Income16,023,000USD
    Interest Income7,750,000USD
    Interest Expense95,000USD
    Net Interest Income7,655,000USD
    Income Before Tax7,759,000USD
    Income Tax Expense305,000USD
    Tax Provision305,000USD
    Net Income7,454,000USD
    Net Income From Continuing Ops7,454,000USD
    Ebit7,854,000USD
    Ebitda19,761,000USD
    Depreciation And Amortization11,907,000USD
    Reconciled Depreciation11,907,000USD
    Total Other Income Expense Net-8,264,000USD
    SourceLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets729,696,000USD700,727,000USD632,654,000USD327,521,000USD312,633,000USD312,633,000USD302,059,000USD—
    Cash And Equivalents548,628,000USD———————
    Total Current Assets651,376,000USD624,138,000USD560,558,000USD251,716,000USD236,153,000USD236,153,000USD227,817,000USD—
    Other Current Assets6,719,000USD6,166,000USD5,421,000USD4,529,000USD3,022,000USD3,022,000USD2,898,000USD—
    Other Non Current Assets5,559,000USD———————
    Total Liabilities192,890,000USD———————
    Total Current Liabilities55,725,000USD57,162,000USD47,962,000USD40,785,000USD39,874,000USD39,874,000USD28,386,000USD—
    Total Stockholder Equity536,806,000USD505,620,000USD480,105,000USD179,896,000USD169,156,000USD169,407,000USD167,753,000USD—
    Total Equity Including Noncontrolling Interest536,806,000USD———————
    Deferred Revenue2,328,000USD———————
    Deferred Revenue Non Current0USD———————
    Net Receivables74,894,000USD61,305,000USD41,617,000USD34,646,000USD30,438,000USD30,438,000USD24,709,000USD—
    Inventory21,135,000USD19,217,000USD17,545,000USD17,389,000USD13,735,000USD13,735,000USD8,733,000USD—
    Property Plant Equipment Net72,761,000USD71,673,000USD67,102,999USD66,691,000USD68,390,000USD68,390,000USD68,850,000USD—
    Accounts Payable12,205,000USD8,702,000USD7,184,000USD7,806,000USD7,948,000USD7,948,000USD4,304,000USD—
    Short Term Debt6,343,000USD6,242,000USD5,598,000USD5,646,000USD5,842,000USD5,842,000USD6,219,000USD—
    Retained Earnings-248,723,000USD-256,777,000USD-274,748,000USD-280,724,000USD-286,435,000USD-286,435,000USD-282,201,000USD—
    Accumulated Other Comprehensive Income-1,792,000USD-1,792,000USD——————
    Total Liab—195,107,000USD152,549,000USD147,625,000USD143,477,000USD143,226,000USD134,306,000USD—
    Other Current Liab—39,422,000USD32,992,000USD24,489,000USD23,868,000USD26,084,000USD15,057,000USD—
    Capital Stock—0USD0USD0USD————
    Cash—537,450,000USD495,975,000USD195,152,000USD188,958,000USD188,958,000USD191,477,000USD—
    Cash And Short Term Investments—537,450,000USD495,975,000USD195,152,000USD188,958,000USD188,958,000USD191,477,000USD—
    Current Deferred Revenue—2,796,000USD2,188,000USD2,683,000USD2,216,000USD—2,806,000USD—
    Net Debt—-393,263,000USD-387,080,000USD-87,014,000USD-82,234,000USD-82,234,000USD-82,101,000USD—
    Short Long Term Debt Total—144,187,000USD108,895,000USD108,138,000USD106,724,000USD106,724,000USD109,376,000USD—
    Long Term Debt—90,005,000USD57,226,000USD54,986,000USD————
    Property Plant Equipment Gross—71,673,000USD89,781,000USD66,691,000USD————
    Common Stock Shares Outstanding—53,028,360shares45,804,755shares44,720,379shares44,720,379shares44,720,379shares44,720,379shares44,720,379shares
    Non Current Assets Total—76,588,999USD72,096,000USD75,805,000USD76,479,999USD76,480,000USD74,242,000USD—
    Non Current Liabilities Total—137,945,000USD104,587,000USD106,840,000USD103,603,000USD103,352,000USD105,920,000USD—
    Non Currrent Assets Other—4,915,999USD4,993,000USD9,114,000USD8,089,999USD8,090,000USD5,392,000USD—
    Net Working Capital—566,976,000USD512,596,000USD210,931,000USD————
    Unclassified Non Current Liabilities—47,940,000USD47,361,000USD47,506,000USD103,603,000USD103,352,000USD105,920,000USD—
    Unclassified Equity—764,189,000USD754,853,000USD460,620,000USD455,591,000USD455,842,000USD449,954,000USD—
    Intangible Assets——587,000USD———227,000USD—
    Non Current Liabilities Other———4,348,000USD————
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USD
    Total Assets632,654,000USD302,059,000USD191,677,000USD
    Intangible Assets587,000USD227,000USD—
    Other Current Assets5,421,000USD2,898,000USD1,941,000USD
    Total Liab152,549,000USD134,306,000USD161,203,000USD
    Total Stockholder Equity480,105,000USD167,753,000USD30,474,000USD
    Other Current Liab32,992,000USD15,057,000USD6,823,000USD
    Capital Stock0USD——
    Retained Earnings-274,748,000USD-282,201,000USD-240,631,000USD
    Cash495,975,000USD191,477,000USD97,268,000USD
    Cash And Short Term Investments495,975,000USD191,477,000USD97,268,000USD
    Total Current Assets560,558,000USD227,817,000USD115,497,000USD
    Total Current Liabilities47,962,000USD28,386,000USD66,803,000USD
    Current Deferred Revenue2,188,000USD2,806,000USD3,024,000USD
    Net Debt-387,080,000USD-82,101,000USD49,078,000USD
    Short Term Debt5,598,000USD6,219,000USD53,745,000USD
    Short Long Term Debt Total108,895,000USD109,376,000USD146,346,000USD
    Long Term Debt57,226,000USD——
    Net Receivables41,617,000USD24,709,000USD9,090,000USD
    Inventory17,545,000USD8,733,000USD7,198,000USD
    Accounts Payable7,184,000USD4,304,000USD3,211,000USD
    Property Plant Equipment Net67,102,999USD68,850,000USD73,866,000USD
    Property Plant Equipment Gross89,781,000USD——
    Common Stock Shares Outstanding45,804,755shares44,720,379shares44,720,379shares
    Non Current Assets Total72,096,000USD74,242,000USD76,180,000USD
    Non Current Liabilities Total104,587,000USD105,920,000USD94,400,000USD
    Non Currrent Assets Other4,993,000USD5,392,000USD2,314,000USD
    Net Working Capital512,596,000USD——
    Unclassified Non Current Liabilities47,361,000USD105,920,000USD94,400,000USD
    Unclassified Equity754,853,000USD449,954,000USD271,105,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation3,567,000USD
    Stock Based Compensation14,726,000USD
    Change To Account Receivables-33,277,000USD
    Change To Inventory-3,590,000USD
    Change To Liabilities4,787,000USD
    Change In Working Capital-29,097,000USD
    Operating Cash Flow24,566,000USD
    Capital Expenditures-8,520,000USD
    Investing Cash Flow-8,520,000USD
    Net Debt Issuance29,699,000USD
    Unclassified Financing Cash Flow6,908,000USD
    Financing Cash Flow36,607,000USD
    Change In Cash52,653,000USD
    End Cash Flow548,628,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Net Income17,970,000USD5,711,000USD-246,000USD-3,988,000USD-11,477,000USD-14,904,000USD
    Depreciation2,990,000USD2,952,000USD1,747,000USD1,793,000USD2,995,000USD2,985,000USD
    Stock Based Compensation6,510,000USD4,475,000USD2,553,000USD2,553,000USD2,307,000USD2,150,000USD
    Other Non Cash Items8,988,000USD4,545,000USD-1,501,000USD2,195,000USD361,000USD2,184,000USD
    Change To Account Receivables-19,688,000USD-4,208,000USD-2,864,500USD-2,864,500USD-1,878,000USD-3,836,000USD
    Change To Inventory-1,672,000USD-3,654,000USD-2,501,000USD-2,501,000USD-891,000USD-716,000USD
    Change In Working Capital-14,518,000USD-7,687,000USD-3,167,000USD-3,167,000USD-2,609,000USD-3,717,000USD
    Total Cash From Operating Activities15,430,000USD9,996,000USD1,903,500USD1,903,500USD-8,423,000USD-9,785,000USD
    Capital Expenditures-4,471,000USD-2,123,000USD-2,610,500USD-2,610,500USD-2,105,000USD-1,548,000USD
    Free Cash Flow10,959,000USD7,873,000USD-707,000USD-707,000USD-10,528,000USD-11,333,000USD
    Total Cashflows From Investing Activities-4,471,000USD-2,123,000USD-2,610,500USD-2,610,500USD-2,105,000USD—
    Net Borrowings29,802,000USD-438,000USD-490,000USD-521,000USD-591,000USD12,476,000USD
    Total Cash From Financing Activities30,516,000USD-1,679,000USD-552,500USD-552,500USD-288,000USD12,364,000USD
    Change In Cash41,475,000USD6,194,000USD188,958,000USD-191,477,000USD-10,816,000USD1,031,000USD
    Begin Period Cash Flow495,975,000USD188,958,000USD191,599,000USD191,477,000USD202,293,000USD201,262,000USD
    End Period Cash Flow537,450,000USD195,152,000USD188,958,000USD191,599,000USD191,477,000USD202,293,000USD
    Unclassified Operating Cash Flow-6,510,000USD—2,517,500USD2,517,500USD—1,517,000USD
    Sale Purchase Of Stock—0USD——0USD0USD
    Issuance Of Capital Stock—0USD——0USD-26,000USD
    Unclassified Financing Cash Flow—-1,241,000USD————
    Other Cashflows From Financing Activities——-552,500USD-552,500USD303,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20242024-12-31 · USDFY 20232023-12-31 · USD
    Net Income-41,570,000USD-82,683,000USD
    Depreciation11,688,000USD6,463,000USD
    Other Non Cash Items5,272,999USD18,755,000USD
    Change To Account Receivables-15,619,000USD-2,588,000USD
    Change To Inventory-1,535,000USD-1,412,000USD
    Change In Working Capital-16,765,999USD3,793,000USD
    Total Cash From Operating Activities-41,375,000USD-53,672,000USD
    Capital Expenditures-5,402,000USD-6,174,000USD
    Free Cash Flow-46,777,000USD-59,846,000USD
    Total Cashflows From Investing Activities-5,433,000USD82,838,000USD
    Total Cash From Financing Activities141,017,000USD13,405,000USD
    Sale Purchase Of Stock-546,000USD—
    Change In Cash94,209,000USD97,268,000USD
    Begin Period Cash Flow97,268,000USD—
    End Period Cash Flow191,477,000USD97,268,000USD
    Other Cashflows From Investing Activities-31,000USD-988,000USD
    Unclassified Financing Cash Flow141,563,000USD—
    Unclassified Investing Cash Flow—90,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductClinical Trial Support And Other Services1,537,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOncology13,663,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductPrenatal94,248,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductClinical Trial Support And Other Services1,143,000USD0002070849-26-000031
    Q1 2026Quarterly · 2026-03-31ProductOncology10,720,000USD0002070849-26-000031
    Q1 2026Quarterly · 2026-03-31ProductPrenatal96,525,000USD0002070849-26-000031
    FY 2025Yearly · 2025-12-31ProductClinical Trial Support And Other Services3,054,000USD0002070849-26-000017
    FY 2025Yearly · 2025-12-31ProductOncology24,953,000USD0002070849-26-000017
    FY 2025Yearly · 2025-12-31ProductPrenatal277,105,000USD0002070849-26-000017
    Q3 2025Quarterly · 2025-09-30ProductClinical Trial Support And Other Services761,000USD0001628280-25-056321
    Q3 2025Quarterly · 2025-09-30ProductOncology8,691,000USD0001628280-25-056321
    Q3 2025Quarterly · 2025-09-30ProductPrenatal74,071,000USD0001628280-25-056321
    Q1 2025Quarterly · 2025-03-31ProductClinical Trial Support And Other Services710,000USD0002070849-26-000031
    Q1 2025Quarterly · 2025-03-31ProductOncology2,177,000USD0002070849-26-000031
    Q1 2025Quarterly · 2025-03-31ProductPrenatal56,076,000USD0002070849-26-000031
    FY 2024Yearly · 2024-12-31ProductClinical Trial Support And Other Services3,737,000USD0002070849-26-000017
    FY 2024Yearly · 2024-12-31ProductOncology2,944,000USD0002070849-26-000017
    FY 2024Yearly · 2024-12-31ProductPrenatal145,901,000USD0002070849-26-000017
    Q3 2024Quarterly · 2024-09-30ProductClinical Trial Support And Other Services680,000USD0001628280-25-056321
    Q3 2024Quarterly · 2024-09-30ProductOncology1,138,000USD0001628280-25-056321
    Q3 2024Quarterly · 2024-09-30ProductPrenatal36,601,000USD0001628280-25-056321
    FY 2023Yearly · 2023-12-31ProductClinical Trial Support And Other Services2,926,000USD0002070849-26-000017
    FY 2023Yearly · 2023-12-31ProductOncology0USD0002070849-26-000017
    FY 2023Yearly · 2023-12-31ProductPrenatal68,803,000USD0002070849-26-000017

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.